GlassScriptPhysician profile
Rahman Shah
NPI 1780632380
$1,980.32
in general payments reported to CMS, 2019-2025
18 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $567 · 2021: $377 · 2022: $248 · 2023: $280 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $319.43 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $233.46 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $219.94 | 2020-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $203.78 | 2019-2025 | Lifevest |
| Amgen INC. | $201.44 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $194.07 | 2020-2022 | |
| Amarin Pharma, INC. | $162.92 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $128.90 | 2019-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $77.89 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.97 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.85 | 2022-2023 | Eliquis |
| Pfizer INC. | $36.08 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $30.50 | 2022-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $24.37 | 2021 | |
| Medtronic, INC. | $21.15 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.39 | 2020 | |
| Philips North America LLC | $14.73 | 2023 | |
| Alk-Abello, INC | $14.45 | 2023 | Odactra, Ragwitek, Grastek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahman Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.